-
1.发明公开
公开(公告)号：EP0698015A1
公开(公告)日：1996-02-28
申请号：EP94917338.0
申请日：1994-05-10
发明人： MARSTERS, James, C., Jr. , BROWN, Michael, S. , CROWLEY, Craig, W. , GOLDSTEIN, Joseph, L. , JAMES, Guy, L. , McDOWELL, Robert, S. , OARE, David , RAWSON, Thomas, E. , REYNOLDS, Mark , SOMERS, Todd, G.
IPC分类号： A61K31 , A61P31 , A61P35 , C07D223 , C07D243 , C07D401 , C07D403 , C07D405 , C07D409 , C07D417 , C07D487 , C07D498 , C07D513 , C07K5 , A61K38
CPC分类号： C07D223/16 , A61K38/00 , C07D243/10 , C07D243/24 , C07D401/06 , C07D401/14 , C07D403/06 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/06 , C07D409/14 , C07D487/04 , C07D513/04 , C07K5/0207 , C07K5/0606 , C07K5/06139 , C07K5/06191 , C07K5/081 , C07K5/0821 , C07K5/0827 , C07K5/1013 , C07K5/1024 , C07K5/1027
摘要： Benzodiazepine derivatives are disclosed that act as potent inhibitors of ras farnesyl:protein transferase. Pharmaceutical compositions containing these benzodiazepines are provided for treatment of diseases for which inhibition of the ras farnesyl:protein transferase is indicated.
-
公开(公告)号：EP0728147B1
公开(公告)日：2003-02-12
申请号：EP95901112.3
申请日：1994-11-04
申请人： GENENTECH, INC.
摘要： Human receptor selective atrial natriuretic factor variants containing various substitutions, especially G16R, show equal potency and binding affinity for the human A-receptor but have decreased affinity for the human clearance or C-receptor. These ANF variants have natriuretic, diuretic and vasorelaxant activity but have increased metabolic stability, making them suitable for treating congestive heart failure, acute kidney failure and renal hypertension.
-
公开(公告)号：EP1347968A1
公开(公告)日：2003-10-01
申请号：EP01997016.9
申请日：2001-11-26
申请人： GENENTECH, INC.
发明人： BURDICK, Daniel, J. , GADEK, Thomas, R. , MARSTERS James, C., Jr. , OARE, David , REYNOLDS, Mark, E. , STANLEY, Mark, S.
IPC分类号： C07D405/12 , C07D417/12 , C07D207/16 , A61P37/06 , A61K31/34 , A61K31/425 , A61K31/40
CPC分类号： C07D405/12 , A61K31/198 , A61K31/40 , A61K31/44 , C07D207/16 , C07D277/06 , C07D307/54 , C07D417/12
摘要： The invention relates to novel compounds having formula (I), wherein Cy, X, Y, L and R1-6 are as defined herein. The compounds bind CD11/CD18 adhesion receptors such as Lymphocyte Function-associated Antigen-1 (LFA-1) and are therefore useful for treating disorders mediated by LFA-1 such as inflammation
-
公开(公告)号：EP0728147A1
公开(公告)日：1996-08-28
申请号：EP95901112.0
申请日：1994-11-04
申请人： GENENTECH, INC.
IPC分类号： C12N15 , A61K38 , A61P1 , A61P3 , A61P7 , A61P9 , A61P13 , A61P15 , C07H21 , C07K14 , C12P21 , C12R1
摘要： Human receptor selective atrial natriuretic factor variants containing various substitutions, especially G16R, show equal potency and binding affinity for the human A-receptor but have decreased affinity for the human clearance or C-receptor. These ANF variants have natriuretic, diuretic and vasorelaxant activity but have increased metabolic stability, making them suitable for treating congestive heart failure, acute kidney failure and renal hypertension.
-
-
-
搜索结果
4 条记录 (耗时 0.015 秒)
